Table of Contents

Cordis Corporation (USA)

Duke University (USA)

Elixir Medical Corporation (USA)

ELLA-CS, s.r.o. (Czech Republic)

Ethicon, Inc. (USA)

Eurocor GmbH (Germany)

JMS Co., Ltd. (Japan)

Kyoto Medical Planning Co., Ltd. (Japan)

Medicines Co. (The) (USA)

Medtronic, Inc. (USA)

Poly-Med, Inc. (USA)

Reva Medical Inc. (USA)

Tepha, Inc. (USA)

Xenogenics Corporation (USA)

4.2 Major Activities/Product Launches

First implantation of Elixir Medical's DESolve® Novolimus Eluting Coronary Scaffold System in Europe

BIOTRONIK Reports Use of First–in–Human Use of Bioabsorbable Magnesium DREAMS Scaffold

Elixir Reports Outstanding 1-year Results for Safety and Efficacy for 100% Bioresorbable DESolve® Novolimus Eluting Coronary Scaffold System

Elixir's DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System Certified by CE

Asian Heart Institute Conducts Angioplasty with New Generation Biodegradable Stent

Elixir Medical Finalizes the Enrollment for the DESolve Nx Pivotal Trial Carried Out for Fully Bioresorbable Coronary Scaffold System

REVA Medical Presents the First Follow-Up Imaging Assessment of the ReZolve® Scaffold

Arterial Remodeling Technologies (ART) Announces First Human Use of Its Bioresorbable Stent

Biotronik Announces Positive Results from BIOSOLVE-I trial

American Heart Association Reports Igaki Tamai Biodegradable Stent Safe for Long-Term Treatment of Coronary Artery Disease

Reva Medical's ReZolve™ Stent Bring a New Revolution to Cardiology: Claims to Stop Heart Attacks before they Occur with Resorbable Stents